AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|May 9, 2017
Zephyr Health Announces Certification in Veeva CRM MyInsights
Advertisement
Yesterday, at the 2017 Veeva Global Commercial & Medical Summit,
Veeva revealed a new certification program that offers customers an ecosystem of providers trained to create pre-built dashboards and custom data visualizations. Zephyr Health is one of the first to join the
Advertisement
Related to this article
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
The Battle to Own the GLP-1 Patient Journey
5